Next Biomedical Co.,Ltd. (KOSDAQ:389650)

Next Biomedical Statistics

Total Valuation

Next Biomedical has a market cap or net worth of KRW 546.38 billion. The enterprise value is 517.09 billion.

Market Cap	546.38B
Enterprise Value	517.09B

Important Dates

The last earnings date was Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Next Biomedical has 8.20 million shares outstanding. The number of shares has increased by 13.65% in one year.

Current Share Class	8.20M
Shares Outstanding	8.20M
Shares Change (YoY)	+13.65%
Shares Change (QoQ)	+3.55%
Owned by Insiders (%)	31.75%
Owned by Institutions (%)	9.19%
Float	5.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	33.16
PB Ratio	11.36
P/TBV Ratio	11.43
P/FCF Ratio	n/a
P/OCF Ratio	437.06
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1,662.23
EV / Sales	31.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-271.93

Financial Position

The company has a current ratio of 5.38, with a Debt / Equity ratio of 0.16.

Current Ratio	5.38
Quick Ratio	4.89
Debt / Equity	0.16
Debt / EBITDA	n/a
Debt / FCF	-4.06
Interest Coverage	-1.96

Financial Efficiency

Return on equity (ROE) is -0.67% and return on invested capital (ROIC) is -0.80%.

Return on Equity (ROE)	-0.67%
Return on Assets (ROA)	-0.76%
Return on Invested Capital (ROIC)	-0.80%
Return on Capital Employed (ROCE)	-1.40%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.28
Inventory Turnover	1.79

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +66.80% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+66.80%
50-Day Moving Average	72,862.00
200-Day Moving Average	68,224.50
Relative Strength Index (RSI)	45.11
Average Volume (20 Days)	113,833

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Next Biomedical had revenue of KRW 16.48 billion and -311.08 million in losses. Loss per share was -38.00.

Revenue	16.48B
Gross Profit	11.45B
Operating Income	-719.54M
Pretax Income	-311.08M
Net Income	-311.08M
EBITDA	-201.04M
EBIT	-719.54M
Loss Per Share	-38.00

Balance Sheet

The company has 37.00 billion in cash and 7.71 billion in debt, with a net cash position of 29.29 billion or 3,569.74 per share.

Cash & Cash Equivalents	37.00B
Total Debt	7.71B
Net Cash	29.29B
Net Cash Per Share	3,569.74
Equity (Book Value)	48.11B
Book Value Per Share	5,716.70
Working Capital	35.22B

Cash Flow

In the last 12 months, operating cash flow was 1.25 billion and capital expenditures -3.15 billion, giving a free cash flow of -1.90 billion.

Operating Cash Flow	1.25B
Capital Expenditures	-3.15B
Depreciation & Amortization	518.51M
Net Borrowing	-3.33B
Free Cash Flow	-1.90B
FCF Per Share	-231.79

Margins

Gross margin is 69.49%, with operating and profit margins of -4.37% and -1.89%.

Gross Margin	69.49%
Operating Margin	-4.37%
Pretax Margin	-1.89%
Profit Margin	-1.89%
EBITDA Margin	-1.22%
EBIT Margin	-4.37%
FCF Margin	n/a

Dividends & Yields

Next Biomedical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.65%
Shareholder Yield	-13.65%
Earnings Yield	-0.06%
FCF Yield	-0.35%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Next Biomedical has an Altman Z-Score of 23.68 and a Piotroski F-Score of 5.

Altman Z-Score	23.68
Piotroski F-Score	5